| INTRODUCTION
The renin-angiotensin system (RAS) may promote atherosclerotic processes by the inducing of inflammation, endothelial dysfunction, and low-density lipoprotein (LDL) oxidation. [1] [2] [3] Several studies have
shown upregulation of tissue angiotensin converting enzyme and angiotension-II receptor type 1 (AT1 receptor) in human atherosclerotic plaques, 4, 5 suggesting a potential role of tissue RAS in atherogenesis through local angiotension-II effects. [6] [7] [8] Angiotensin-II may promote atherosclerotic plaque inflammation, 3 and AT1 receptor blockers suppress plaque progression and induce plaque stabilization. 9, 10 However, beneficial antiatherosclerotic properties of AT1 receptor blockers beyond blood pressure control have not yet been established. Although AT1 receptor blockers and calcium channel blockers are commonly used in patients with atherosclerotic cardiovascular disease, little is known about the comparative effects of these two agents on atherosclerotic plaque inflammation. Fimasartan, a potent AT1 receptor blocker, has been shown to have antiatherosclerotic effects in a rabbit model of atherosclerosis. 11 We hypothesized that fimasartan is superior to amlopidine in reducing atherosclerotic plaque inflammation despite similar blood pressure reduction efficacy.
The present study compared the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation in patients with acute coronary syndrome (ACS) using gov number, NCT02378064). FDG PET/CT scans were performed within 2 days of coronary angiography or percutaneous coronary intervention (3-5 days after admission). Eligible patients meeting all the inclusion and none of the exclusion criteria were randomized at 1:1 ratio to receive either fimasartan (60 mg once a day for 6 months) or amlodipine (5 mg once a day for 6 months). All patients were required to take standard medications including antiplatelet agents and cholesterol-lowering drugs and were requested to have a follow-up 18 FDG PET/CT examination at 6 months. Biochemical laboratory tests were also required at admission and at 6-month follow-up. The study protocol was approved by our Institutional Review Committee, and written informed consent was obtained from all patients. 
| METHODS

| Study design
| Image analysis
Image analysis was performed on a dedicated workstation. 
| Statistical analysis
| RESULTS
A total of 146 patients with ACS were screened for enrollment (Table 2) . At 6-month followup, total cholesterol and LDL cholesterol levels significantly decreased in both groups (P < 0.001). High-sensitivity C-reactive protein levels significantly decreased in the fimasartan group (P = 0.017), but not in the amlodipine group (P = 0.068). Triglyceride and HDL cholesterol levels did not significantly change in both groups. Figure 2 shows representative images of improved 18 FDG uptake in carotid plaque after fimasartan or amlodipine therapy, and Table 3 shows 
| DISCUSSISON
Among patients with ACS and carotid artery disease, we found that MDS TBR of the carotid arteries and aorta significantly decreased in 
18
FDG uptakes markedly decreased at the 6-month follow-up. CT, computed tomography; 18 FDG, 18 F-fluorodeoxyglucose; PET, positron emission tomography both fimasartan-and amlodipine-treated patients. Whole vessel TBR of the index vessel significantly decreased in the fimasartan group, but not in the amlodipine group whereas those of aorta decreased in both groups. However, this effect did not differ significantly between the two groups, suggesting similar effects from both agents on atherosclerotic plaque inflammation. Improvement in total cholesterol, LDL cholesterol, and high sensitivity C-reactive protein was also observed without between group differences.
Inflammation derives the atherosclerotic process, providing an important target for in-vivo atherosclerosis imaging studies. 18 FDG accumulates in atherosclerotic plaques in proportion to macrophage concentration, and arterial uptake correlates with arterial inflammatory burden. 12,13 The
FDG PET signal is reproducible, providing a useful tool to assess serial changes of atherosclerotic plaque inflammation. Whole vessel TBR assesses both diseased and healthy segments, whereas MDS TBR reflects inflammatory activity of the diseased segment. The latter is more commonly used to evaluate therapeutic intervention impacts on atherosclerotic plaque inflammation.
The present study showed that inflammatory indexes by 18 FDG PET decreased equally in both groups, suggesting the drugs have similar effects on atherosclerotic plaque inflammation.
Antiatherosclerotic effects of RAS blockers appear to be independent of blood pressure reduction and may be in part due to RAS attenuation. 14 Tissue RAS produces local angiotensin-II that exerts various actions on the cardiovascular system. 15 The ongoing telmisartan alone and in combination with ramipril global endpoint (ONTARGET) trial showed that telmisartan was an equally effective alternative to ramipril to prevent cardiovascular events. 16 The impact of olmesartan on the progression of coronary atherosclerosis: evaluation by intravascular ultrasound (OLIVUS) trial showed that olmesartan led to a significant coronary plaque regression compared with the control group over the 14-month follow-up period. 10 High-dose fimasartan treatment suppressed atherosclerotic plaque development, lipid deposition, macrophage infiltration in a rabbit model of atherosclerosis. 11 However, the present study showed no significant difference between fimasartan and amlodipine in reducing carotid atheroscle- Statins were only used by 50% of OLIVUS trial patients, and LDL cholesterol levels were 104 mg/dL at follow-up, which is above the current recommended limits. In contrast, all patients used statins in the current study, and LDL cholesterol levels were 82 mg/dL at 6-month follow-up. Intensive lipid lowering therapy may dilute RAS blocker effects on atherosclerotic plaque inflammation, leading to similar results in both groups.
Amlodipine is a long-acting calcium channel blocker commonly used as an antihypertensive and antianginal, and anti-inflammatory effects and antioxidant properties have been suggested. 17 The prospective randomized evaluation of the vascular effects of norvasc trial (PREVENT) trial showed that amlodipine reduced carotid intima-media thickness progression rate despite having no effect on angiographic progression of coronary atherosclerosis. 18 The comparison of amlodipine vs enalapril to limit occurrences of thrombosis (CAMELOT) study showed that major adverse cardiovascular events were similarly reduced for both amlodipine and enalapril treated patients. 19 The present study showed that atherosclerotic plaque inflammation similarly decreased in both groups with no blood pressure differences. These findings are inconsistent with those from other calcium channel blocker clinical trials, 20 suggesting that amlodipine may have additional beneficial effects not mediated through blood pressure reduction.
Several classes of antihypertensive drugs have been used to control blood pressure, but optimal pharmacological agent choice is not yet fully established. Two clinical trials showed angiotensin converting enzyme inhibitor benefits for patients with coronary artery disease and normal or borderline blood pressure, whereas other trials showed no additional benefits beyond blood pressure. [6] [7] [8] The antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT) showed no differences of major cardiovascular events among lisinopril, diuretic, and amlodipine therapies. 21 The valsartan antihypertensive long-term use evaluation (VALUE) study showed similar event reduction for valsartan compared with amlodipine. 22 The present study showed similar reductions of carotid or aorta inflammation, consistent Nominal change was calculated as follow-up-baseline, and percent change as (follow-up-baseline)/baseline × 100. Abbreviations: MDS, most diseased segment; TBR, tissue blood ratio.
with previous clinical trials that did not show superior outcomes for antihypertensive agents that modulate the RAS.
This study has several limitations. First, the analysis was limited by the small number of patients, which may have impacted the power to detect subtle differences in arterial inflammation. Second, our study was an open label, single center study, which is subject to inherent limitations. However, we tried to minimize these limitations by using blind 18 FDG PET/CT evaluations.
